Services on Demand
Journal
Article
Spanish (pdf)
Article in xml format
Article references
Automatic translation
Send this article by e-mailIndicators
Cited by SciELO 
Access statistics
Related links
Similars in
SciELO
Share
Permalink
Medicina interna de México
Print version ISSN 0186-4866
Abstract
HERRERA-GARCIA, José Carlos et al. Administration of omalizumab in Mexican patients diagnosed with moderate-severe non-atopic asthma. Med. interna Méx. [online]. 2018, vol.34, n.6, pp.833-839. ISSN 0186-4866. https://doi.org/10.24245/mim.v34i6.2091.
OBJECTIVE
To determine the clinical improvement in patients diagnosed with moderate-severe non-atopic asthma in treatment with omalizumab.
MATERIAL AND METHOD
A prospective and observational study was made from January 1st 2017 to January 1st 2018 in adult patients who, despite daily treatment with or without maintenance oral corticosteroids, had uncontrolled moderate to severe non-atopic asthma; patients were assigned to receive omalizumab at doses of IgE levels. The primary endpoint was the change in the clinical and functional parameters of the patients by means of Asthma Control Test.
RESULTS
There were included 20 patients. After 52 weeks of administration of omalizumab they showed a moderate increase in FEV1 and in clinical and functional parameters. The symptomatic improvement of the patients was mainly considered by an increase of 10 to 20 points in Asthma Control Test. Good tolerance to the drug was also observed, without any serious adverse effects, as well as improvement in the quality of life of the patients.
CONCLUSIONS
Omalizumab has a therapeutic role in moderate to severe non-atopic asthma. Our results support the clinical efficacy of omalizumab in Mexican non-atopic asthmatic patients.
Keywords : Asthma; Omalizumab; Quality of life.
